First Tracks Biotherapeutics

First Tracks Biotherapeutics P/CF

The P/CF (Price-to-Cash-Flow Ratio) of First Tracks Biotherapeutics (TRAX) as of Oct 17, 2026 is -4.25. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -4.83 — a change of -11.98% (higher).

P/CF

-4.25

YoY

-11.98%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of First Tracks Biotherapeutics is 2025 -4.25 . P/CF (Price-to-Cash-Flow Ratio) of First Tracks Biotherapeutics was 2024 -4.83 . It decreases by -11.98% higher compared to the previous year.

The First Tracks Biotherapeutics P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2023
-6.54 USD
Jan 1, 2024
-4.83 USD
Jan 1, 2025
-4.25 USD
The First Tracks Biotherapeutics P/CF history
YEARP/CFYoY
-4.25-11.98%
-4.83-26.07%
-6.54—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

First Tracks Biotherapeutics Stock analysis

What does First Tracks Biotherapeutics do? First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, United States, developing immunology therapeutics for autoimmune and inflammatory diseases. The company focuses on innovative treatments including ANB033, a novel anti-CD122 antagonist targeting IL-15 and IL-2 receptors, Rosnilimab, which selectively depletes pathogenic T cells, and ANB101, a BDCA2-modulating antibody targeting plasmacytoid dendritic cells. Founded in 2019, it operates in the United States with a focus on advancing therapies for complex immune conditions. First Tracks Biotherapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about First Tracks Biotherapeutics stock

P/CF (Price-to-Cash-Flow Ratio) of First Tracks Biotherapeutics is -4.25 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of First Tracks Biotherapeutics changed from -4.83 to -4.25, representing a -11.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) First Tracks Biotherapeutics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s First Tracks Biotherapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — First Tracks Biotherapeutics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — First Tracks Biotherapeutics